1. Pink Sheet
  2. >>Geography
  3. >>Europe

Gene Therapy Libmeldy Undergoes Cross-Country HTA In Europe

 
• By Francesca Bruce

Cross-country drug access coalition BeNeLuxA is reviewing the costly one-off gene therapy for children with metachromatic leukodystrophy.

Vector of business people sitting at target table brainstorming idea
Orchard's gene therapy Libmeldy could be subject to cross-country price negotiations • Source: Shutterstock

BeNeLuxA, the cross-country initiative in Europe focused on access to medicines, is conducting a joint health technology assessment (HTA) of what is reportedly the world’s most expensive drug, Libmeldy (atidarsagene autotemcel), a gene therapy from Orchard Therapeutics. Joint price negotiations for the product could follow depending on the outcome of the HTA assessment, says the initiative, made up of Belgium, the Netherlands, Luxembourg, Austria and Ireland.

Industry and other stakeholders will be playing close attention to how the assessment plays out and whether joint pricing negotiations follow as the EU moves towards closer collaboration on HTAs and joint clinical assessments. In October, Belgian minister of health, Frank Vandenbroucke, described BeNeLuxA as the “gold standard for voluntary collaborations between member states

BeNeLuxA

BeNeLuxA is the most advanced of several cross-country collaborations in Europe that aim to make access to medicines more sustainable. It comprises Belgium, the Netherlands, Luxembourg, Austria and Ireland.

Areas of cooperation include: horizon scanning, information sharing and policy exchange, health technology assessments, and pricing and reimbursement

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Few Takers For EMA’s OPEN Pathway Prompts Rethink

 
• By Vibha Sharma

While drug companies say they support the European Medicines Agency’s expanded OPEN framework for the collaborative assessment of marketing applications with non-EU authorities, they are reluctant to participate in the initiative for a number of reasons.

EU Council Could Adopt Pharma Reform Package Next Week, But Disputes Risk A Year’s Delay

 
• By Eliza Slawther

The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

More from Geography

Mayne’s Nextstellis Promo Wrong To Suggest Better Safety Than Other Contraceptives, FDA Says

 
• By Sue Sutter

A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 
• By Ramsey Baghdadi

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.

US FDA Waiting On Guidance Agenda Future As HHS Seeks Regulation Cuts

 
• By Derrick Gingery

The FDA continues to wait for a decision on whether its priority guidances will be published as HHS asks the public for potential regulation cuts to fulfill President Trump’s executive order.